Tisagenlecleucel
Leukemia, B-Cell
Chongqing Precision Biotech Co., LtdCell therapyPhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
2 Active assets in the Leukemia, B-Cell cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE St. Jude Children's Research Hospital | Phase 2 | BB |
Cytosin-Arabinosid Children's Oncology Group | Phase 2 | B |
Solu-Cortef Children's Oncology Group | Phase 2 | B |
Cyclophosphamide Dana-Farber Cancer Institute | Phase 2 | B |
Inno-206 Children's Oncology Group | Phase 2 | B |
View all 22 →
Same molecule, other indications
Tisagenlecleucel is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →